Navigation Links
WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
Date:6/22/2009

SHANGHAI, June 22 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology, and medical device research and development outsourcing company with operations in China and the United States, today announced that Felix Hsu has been appointed Senior Vice President of WuXi AppTec U.S.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Prior to joining WuXi, Mr. Hsu worked at Medtronic for 14 years in positions of increasing responsibility. He has broad experience as a product manager and business leader, serving as Director of Heart Valve Worldwide Marketing; Vice President of Business Excellence; Vice President of Cardiac Surgery for Asia Pacific, based in Hong Kong; and Vice President of Supply Chain Integration based in Minneapolis. Prior to working at Medtronic, he served in product management, sales management, and strategic planning roles at Abbott Laboratories and as a business manager at Sabratek. In these roles, he was successful in driving revenue growth through effective product management and in implementing strategies to improve operational excellence and reduce costs.

In his new role, Mr. Hsu will be responsible for WuXi's U.S. business. A significant portion of U.S. revenues are derived from serving the medical device industry, where Mr. Hsu has extensive experience. He will report to Edward Hu, Chief Operating Officer, acting Chief Financial Officer, and current head of U.S. operations.

"I am very pleased to welcome Felix on board as we continue to strengthen our U.S. management team," commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Our U.S. operations offer a range of testing services critical to the successful development and regulatory approval of new biologics and medical devices. We expect our U.S. business will grow under Felix's leadership."

Mr. Hsu received a bachelor's degree in Electrical Engineering from General Motors Institute and an MBA from the University of Michigan.

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
Breaking Biology Technology:
(Date:11/30/2016)... Nov. 30, 2016 Not many of us realize that we spend ? ... so we need to do it well. Inadequate sleep levels have been found to ... stroke, diabetes, and even cancer. Maybe now is the best time to ... help them to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... 29, 2016 Nearly one billion matches per second ... ... DERMALOG is Germany's ... efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification ...
(Date:11/22/2016)... , Nov. 22, 2016   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... Medical LiveWire Healthcare and Life Sciences Awards as ... caps off an unprecedented year of recognition and growth ... for over 15 years. iMedNet ...
Breaking Biology News(10 mins):